Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus Clinical Trial

— ENDURE  

Official title:

A Multicenter, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Durability of the Efficacy and Safety of Alogliptin Compared to Glipizide When Used in Combination With Metformin in Subjects With Type 2 Diabetes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00856284
• Other study ID #: SYR-322_305
• Secondary ID: 2008-007444-34U1
• Status: Completed
• Phase: Phase 3
• First received: March 4, 2009
• Last updated: September 25, 2013
• Start date: March 2009
• Est. completion date: October 2012

Study information

• Verified date: September 2013
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the safety and effectiveness of adding alogliptin, once daily (QD), compared to glipizide with metformin in diabetic patients.

Description:

For patients diagnosed with type 2 diabetes mellitus, metformin is the usual first-line therapy in addition to diet control and exercise. For those patients with inadequate glycemic control with metformin monotherapy or experiencing serious side effects of metformin, sulfonylurea is a popular choice as a second-line oral antidiabetic treatment.

Alogliptin is a dipeptidyl peptidase-4 inhibitor currently being developed by Takeda for use in patients with type 2 diabetes mellitus.

This study is designed to further explore the durability of efficacy and safety of alogliptin compared to glipizide in type 2 diabetes mellitus patients whose blood sugar level is inadequately controlled with metformin therapy.

The duration of this study will be approximately 2 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2639
• Est. completion date: October 2012
• Est. primary completion date: October 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Has a diagnosis of type 2 diabetes mellitus.

• Must meet one of the following:

• Has been inadequately controlled on a stable daily dose of =1500 mg (or documented maximum tolerated dose) of metformin for at least 2 months prior to Screening.

• Has been inadequately controlled (as defined by a glycosylated hemoglobin 7.5 - 10%, inclusive) on metformin <1500 mg without documented maximum tolerated dose.

• No treatment with antidiabetic agents other than metformin within 2 months prior to Screening (for Schedule A)/Pre-Screening (for Schedule B).

• Has body mass index within 23 kg/m^2 and 45 kg/m^2 unless the patient is Asian or of Asian descent, for whom the allowable body mass index will be = 20 kg/m^2 and = 35 kg/m^2, inclusive.

• Has fasting C-peptide concentration at least 0.8 ng.

• If regularly using non-excluded medications, must be on a stable dose at least 4 weeks prior to Screening/Pre-screening.

• Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant, lactating or intends to donate ova from Screening throughout the duration of the study.

• Must be able and willing to monitor their blood glucose concentrations with a home monitor, and comply with protocol requirements including scheduled clinic appointments.

Exclusion Criteria:

• Systolic blood pressure greater than or equal to 150 mmHg and/or diastolic pressure greater than or equal to 90.

• Hemoglobin less than or equal to 12 g/dL for males and less than or equal to 10 g/dL for females at Screening Visit.

• Alanine aminotransferase greater than or equal to 2.5 times the upper limit of normal at Screening Visit.

• Serum creatinine greater than or equal to 1.5 mg/dL for males and 1.4 for females, or calculated creatinine clearance less than 60 L/min.

• Males intending to impregnate others or donate sperm before, during or within 1 month after participating in the study.

• A history of cancer other than squamous or basal cell carcinoma of the skin that has not been in full remission for at least 5 years.

• A history of laser treatment for diabetic retinopathy within 6 months of screening.

• Treated for diabetic gastric paresis, gastric banding, or gastric bypass.

• New York Heart Association Class III or IV heart failure.

• History of coronary angioplasty, coronary stent placement, coronary bypass surgery, myocardial infarction, stroke or transient ischemic attack within 3 months prior to screening.

• Known history of human immunodeficiency virus, hepatitis B or C.

• Alcohol or substance abuse within 2 years prior to screening.

• Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:

• Any investigational drug within 30 days

• Any investigational diabetic drug within 3 months

• Any antidiabetic drug in the dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 mimetics classes within 90 days prior to Screening other than metformin

• Prior treatment with alogliptin.

• Weight-loss drugs

• Oral or systemically injected glucocorticoids

• A hypersensitivity allergy or anaphylactic reaction to any dipeptidyl peptidase-4 drug, metformin or glipizide.

• Has a documented history or concurrent signs of significant thyroid disease (eg, autoimmune thyroid diseases such as Graves disease and Hashimoto thyroiditis or active thyroid nodules).

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Type 2 Diabetes Mellitus

Intervention

Drug:
• Alogliptin
Alogliptin tablets
• Metformin
Metformin tablets
• Glipizide
Glipizide tablets

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Takeda

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Austria,  Brazil,  Canada,  Chile,  Germany,  Guatemala,  Hong Kong,  Hungary,  India,  Israel,  Italy,  Korea, Republic of,  Latvia,  Lithuania,  Malaysia,  Mexico,  New Zealand,  Peru,  Philippines,  Poland,  Puerto Rico,  Romania,  Russian Federation,  Singapore,  South Africa,  Spain,  Thailand,  Ukraine,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 52	The change from Baseline to Week 52 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound). The least squares (LS) means are from an analysis of covariance (ANCOVA) model with treatment, study schedule, and geographic region as class variables, and Baseline metformin dose and Baseline HbA1c as covariates.	Baseline and Week 52
Primary	Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 104	The change from Baseline to Week 104 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound). The least squares (LS) means are from an analysis of covariance (ANCOVA) model with treatment, study schedule, and geographic region as class variables, and Baseline metformin dose and Baseline HbA1c as covariates.	Baseline and Week 104
Secondary	Change From Baseline in Glycosylated Hemoglobin at Other Time Points	The change from Baseline over time in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound). LS means are from an ANCOVA model with treatment, study schedule, and geographic region as class variables, and Baseline metformin dose and Baseline HbA1c as covariates.	Baseline and Weeks 4, 8, 12, 16, 20, 26, 39, 65, 78, and 91.
Secondary	Change From Baseline in Fasting Plasma Glucose Over Time	The change from Baseline in fasting plasma glucose (FPG) was assessed at Weeks 2, 4, 8, 12, 16, 20, 26, 39, 52, 65, 78, 91, and 104. LS means are from an ANCOVA model with treatment, study schedule, and geographic region as class variables, and Baseline FPG and Baseline metformin dose as covariates.	Baseline and Weeks 2, 4, 8, 12, 16, 20, 26, 39, 52, 65, 78, 91, and 104.
Secondary	Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 6.5%	The percentage of participants with HbA1c less than or equal to 6.5% at Weeks 26, 52, 78, and 104. Participants who did not complete the scheduled Week 104 visit were assessed based on their response at the time of discontinuation.	Weeks 26, 52, 78, and 104.
Secondary	Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 7.0%	Percentage of participants with HbA1c = 7.0% at Weeks 26, 52, 78, and 104. Participants who did not complete the scheduled Week 104 visit were assessed based on their response at the time of discontinuation.	Weeks 26, 52, 78, and 104.
Secondary	Change From Baseline in Body Weight Over Time	LS Means are from an ANCOVA model with treatment, study schedule and geographic region as class variables, and Baseline weight and Baseline metformin dose as covariates.	Baseline and Weeks 12, 26, 39, 52, 65, 78, 91, and 104.